A detailed history of Nisa Investment Advisors, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 16,950 shares of APLS stock, worth $443,751. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,950
Previous 17,250 1.74%
Holding current value
$443,751
Previous $661,000 26.17%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

SELL
$28.84 - $41.15 $8,652 - $12,345
-300 Reduced 1.74%
16,950 $488,000
Q2 2024

Jul 19, 2024

SELL
$38.07 - $59.71 $1.91 Million - $2.99 Million
-50,100 Reduced 74.39%
17,250 $661,000
Q4 2023

Jan 25, 2024

SELL
$37.14 - $64.82 $37,140 - $64,819
-1,000 Reduced 1.46%
67,350 $4.03 Million
Q3 2023

Nov 02, 2023

BUY
$23.65 - $89.22 $1.32 Million - $4.97 Million
55,759 Added 442.85%
68,350 $2.6 Million
Q2 2023

Aug 11, 2023

BUY
$76.68 - $93.31 $209,413 - $254,829
2,731 Added 27.7%
12,591 $1.15 Million
Q1 2023

May 02, 2023

BUY
$46.59 - $66.96 $559 - $803
12 Added 0.12%
9,860 $650,000
Q4 2022

Feb 02, 2023

SELL
$43.24 - $61.04 $648 - $915
-15 Reduced 0.15%
9,848 $509,000
Q3 2022

Nov 07, 2022

BUY
$44.76 - $69.66 $25,199 - $39,218
563 Added 6.05%
9,863 $657,000
Q2 2022

Aug 03, 2022

BUY
$35.07 - $59.21 $260,920 - $440,522
7,440 Added 400.0%
9,300 $421,000
Q1 2022

Apr 29, 2022

SELL
$35.46 - $54.12 $6,737 - $10,282
-190 Reduced 9.27%
1,860 $95,000
Q4 2021

Feb 03, 2022

SELL
$30.74 - $49.16 $89,207 - $142,662
-2,902 Reduced 58.6%
2,050 $83,000
Q3 2021

Oct 18, 2021

BUY
$31.4 - $69.84 $62,862 - $139,819
2,002 Added 67.86%
4,952 $163,000
Q4 2020

Jan 25, 2021

BUY
$30.79 - $57.2 $12,316 - $22,880
400 Added 15.69%
2,950 $169,000
Q3 2020

Oct 20, 2020

BUY
$25.89 - $33.65 $51,780 - $67,300
2,000 Added 363.64%
2,550 $77,000
Q1 2020

Apr 17, 2020

BUY
$17.91 - $44.33 $9,850 - $24,381
550 New
550 $15,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $2.88B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.